In conclusion, our findings suggest a role for both CTLA-4 and PD-1/PD-L1 in the pathogenesis of IBD and indicate that preexisting IBD increases the risk of severe GI adverse events in patients treated with immune checkpoint inhibitors. This evidence concerns the gene PDCD1 and inflammatory bowel disease.